Projected Prostate Cancer Incidence in the Middle East by 2050: Socioeconomic Disparities and Future Implications.

IF 3.2 Q2 ONCOLOGY
JCO Global Oncology Pub Date : 2025-05-01 Epub Date: 2025-05-29 DOI:10.1200/GO-25-00098
James Parisi, Yetkin Tuac, Okan Argun, Garrett Kearney, Luke W Chen, Ozlem Aynaci, Nadeem Pervez, Layth Mula-Hussain, Jonathan E Leeman, Miranda B Lam, Mutlay Sayan
{"title":"Projected Prostate Cancer Incidence in the Middle East by 2050: Socioeconomic Disparities and Future Implications.","authors":"James Parisi, Yetkin Tuac, Okan Argun, Garrett Kearney, Luke W Chen, Ozlem Aynaci, Nadeem Pervez, Layth Mula-Hussain, Jonathan E Leeman, Miranda B Lam, Mutlay Sayan","doi":"10.1200/GO-25-00098","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Prostate cancer poses a significant public health challenge in the Middle East, with advanced-stage diagnoses and high mortality rates. However, projections regarding its future incidence are limited. The aims of this study were to estimate prostate cancer incidence in the region through 2050, to evaluate socioeconomic factors contributing to regional disparities, and to provide insights to inform future health care policies and resource allocation.</p><p><strong>Methods: </strong>Data from the Global Cancer Observatory were analyzed for Middle Eastern countries, with Europe and North America included for comparison. The percentage change in incidence between 2022 and 2050 was compared across regions using the Mann-Whitney <i>U</i> test. Additional subgroup analyses based on income level and Human Development Index were performed using Kruskal-Wallis test. Spearman rank correlation was used to explore the association between incidence trends and socioeconomic indicators.</p><p><strong>Results: </strong>In 2022, Middle Eastern countries reported 50,944 patients with newly diagnosed prostate cancer, accounting for 3.47% of global incidence. The projected increase in prostate cancer incidence by 2050 was significantly higher in the Middle East compared with Europe and North America (mean rank, 12.50 <i>v</i> 1.50; <i>P</i> = .009). Higher income countries exhibited a greater percentage increase (<i>P</i> = .033), and the income level correlated positively with incidence trends (<i>r</i> = 59.6%; <i>P</i> = .006). Countries with increasing incidence rates had a markedly higher percentage change than those expected to decline (<i>P</i> = .031).</p><p><strong>Conclusion: </strong>Prostate cancer incidence in the Middle East is expected to rise substantially by 2050, with socioeconomic disparities influencing disease trends. These findings highlight the urgent need for targeted awareness campaigns, improved screening strategies, enhanced oncology infrastructure, and strengthened cancer registries to mitigate the projected burden and improve outcomes in the region.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500098"},"PeriodicalIF":3.2000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO Global Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/GO-25-00098","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Prostate cancer poses a significant public health challenge in the Middle East, with advanced-stage diagnoses and high mortality rates. However, projections regarding its future incidence are limited. The aims of this study were to estimate prostate cancer incidence in the region through 2050, to evaluate socioeconomic factors contributing to regional disparities, and to provide insights to inform future health care policies and resource allocation.

Methods: Data from the Global Cancer Observatory were analyzed for Middle Eastern countries, with Europe and North America included for comparison. The percentage change in incidence between 2022 and 2050 was compared across regions using the Mann-Whitney U test. Additional subgroup analyses based on income level and Human Development Index were performed using Kruskal-Wallis test. Spearman rank correlation was used to explore the association between incidence trends and socioeconomic indicators.

Results: In 2022, Middle Eastern countries reported 50,944 patients with newly diagnosed prostate cancer, accounting for 3.47% of global incidence. The projected increase in prostate cancer incidence by 2050 was significantly higher in the Middle East compared with Europe and North America (mean rank, 12.50 v 1.50; P = .009). Higher income countries exhibited a greater percentage increase (P = .033), and the income level correlated positively with incidence trends (r = 59.6%; P = .006). Countries with increasing incidence rates had a markedly higher percentage change than those expected to decline (P = .031).

Conclusion: Prostate cancer incidence in the Middle East is expected to rise substantially by 2050, with socioeconomic disparities influencing disease trends. These findings highlight the urgent need for targeted awareness campaigns, improved screening strategies, enhanced oncology infrastructure, and strengthened cancer registries to mitigate the projected burden and improve outcomes in the region.

预计2050年中东地区前列腺癌发病率:社会经济差异和未来影响。
目的:前列腺癌在中东地区是一项重大的公共卫生挑战,其晚期诊断和高死亡率。然而,对其未来发病率的预测是有限的。本研究的目的是估计到2050年该地区前列腺癌的发病率,评估造成地区差异的社会经济因素,并为未来的卫生保健政策和资源分配提供见解。方法:分析来自全球癌症观察站的中东国家的数据,并将欧洲和北美纳入比较。使用曼-惠特尼U测试比较了2022年至2050年间各地区发病率的百分比变化。采用Kruskal-Wallis检验进行基于收入水平和人类发展指数的附加亚组分析。采用Spearman秩相关来探讨发病率趋势与社会经济指标之间的关系。结果:2022年,中东国家报告新诊断前列腺癌50944例,占全球发病率的3.47%。预计到2050年,中东地区前列腺癌发病率的增长明显高于欧洲和北美(平均排名,12.50 vs 1.50;P = .009)。高收入国家的增幅较大(P = 0.033),收入水平与发病率趋势呈正相关(r = 59.6%;P = .006)。发病率上升的国家的百分比变化明显高于预期发病率下降的国家(P = 0.031)。结论:到2050年,中东地区前列腺癌发病率预计将大幅上升,社会经济差异影响疾病趋势。这些发现突出表明,迫切需要开展有针对性的宣传活动,改进筛查策略,加强肿瘤学基础设施,加强癌症登记,以减轻该地区预计的负担并改善结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JCO Global Oncology
JCO Global Oncology Medicine-Oncology
CiteScore
6.70
自引率
6.70%
发文量
310
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信